{"id":481240,"date":"2020-04-24T15:04:02","date_gmt":"2020-04-24T15:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=481240"},"modified":"2020-04-24T15:04:02","modified_gmt":"2020-04-24T15:04:02","slug":"travelers-diarrhea-pipeline-insights-emerging-therapies-that-shall-shift-the-travelers-diarrhea-market-landscape-positively","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/travelers-diarrhea-pipeline-insights-emerging-therapies-that-shall-shift-the-travelers-diarrhea-market-landscape-positively_481240.html","title":{"rendered":"Traveler’s Diarrhea Pipeline Insights: Emerging therapies that shall shift the Traveler’s Diarrhea Market landscape positively"},"content":{"rendered":"
\"Traveler's<\/a><\/p>\n
\n
Traveler’s Diarrhea Pipeline Insights<\/div>\n<\/div>\n<\/div>\n
\u201cTraveler’s Diarrhea Pipeline Insight, 2020\u201d report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Traveler’s Diarrhea market. In the report, a detailed Traveler’s Diarrhea pipeline landscape is provided including the disease overview and Traveler’s Diarrhea treatment guidelines. <\/div>\n

“Traveler’s Diarrhea Pipeline Insight, 2020<\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Traveler’s Diarrhea market.<\/p>\n

Traveler’s Diarrhea Market Outlook <\/strong><\/p>\n

According to DelveInsight, Traveler’s Diarrhea market in 7MM is expected to increase in the study period 2017-2030 from USD 1,717 Million in 2017 owing to the upcoming therapies.<\/p>\n

The United States accounts for the largest Traveler’s Diarrhea market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan owing to the largest number of incident population.<\/p>\n

Traveler’s Diarrhea Pipeline Drugs <\/strong><\/p>\n

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Traveler’s Diarrhea key players involved in developing targeted therapeutics. <\/p>\n

The late stage product Bismuth<\/strong> Subsalicylate<\/strong> has emerged as a promising option to enter the market in 2021 for Traveler’s Diarrhea. Another mid stage product Etvax<\/strong> is a vaccine against diarrheal disease caused by ETEC expected to enter the market by 2023.<\/p>\n

 \"\"<\/a><\/p>\n

In the report, a detailed Traveler’s Diarrhea pipeline landscape is provided including the disease overview and Traveler’s Diarrhea treatment guidelines. The assessment part of the report embraces in-depth Traveler’s Diarrhea commercial assessment and clinical assessment of the Traveler’s Diarrhea pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s Diarrhea collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Request for sample pages<\/a><\/p>\n

Scope of the report <\/strong><\/p>\n